



**Company name:** Minapharm pharmaceutical

an audited Consolidated financial indicator for the financial year period ended on 30/09/2024.

Currency: EGP

(The form should include the company's comment on the results of the business with the most important factors that led to profit/loss)

**First, the Consolidated financial indicators**

(A) statement Consolidated of profit or loss for the year/period ended in 30/09/2024

	Current period	comparative financial statements	change%
Revenue/sales	3,580,381,968.00	3,049,565,893.00	17%
Total profit (loss)	1,070,497,277.00	1,086,037,077.00	-1%
The ratio of total profit to revenue/sales	0.30	0.36	-16%
Net profit (loss) before tax from continuing activities	76,599,182.00	245,159,377.00	-69%
Net profit (loss) before tax from non-continuing activities (if any)	-	-	0%
Net profit (loss) after tax	14,532,845.00	156,256,525.00	-91%
Earnings / (losses) per share (EPS)	6.51-	13.17	-149%
Diluted share of profit / loss (if any)	-	-	0%

شركة مينافارم للأدوية والصناعات الكيماوية  
ط ٢ ش. البرديس من أسماء فهمى  
خلف الرقابة الإدارية - أرض الجولف

**Head Office:** 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt  
**Factory:** 10<sup>th</sup> of Ramadan City - Egypt



(B) Statement Consolidated of financial position in 30/09/2024

	Current period	comparative financial year (previous Year)	change%
Net working capital	780,879,946.00	511,263,937.00	53%
Owner's equity	4,323,155,091.00	3,422,705,618.00	26%
Paid capital	122,934,400	122,934,400	0%
Reserves	2,534,565,382.00	1,579,403,760.00	60%
Retained earnings	1,788,589,709.00	1,843,301,858.00	-3%
The profit (loss) of the period	14,532,845.00	156,256,525.00	-91%
Other			
Treasury Shares	69,626,535	69,626,535	0%

(C) cash flow Consolidated statement for the year 30/09/2024

	Current period	comparative financial statements	Change%
Cash flows from (to) operating activities	78,825,301.00	21,228,418.00	271%
Cash flows from (to) investment activities	341,662,653.00-	1,142,070,892.00-	-70%
Cash flows from (to) financing activities	1,400,184,018.00	952,819,865.00	47%

Second: Material events that have occurred since the date of the financial results till now and should be disclosed.

Head Office: 2T Taksim Asmaa Fahmy Nasr City - Cairo - Egypt  
Factory: 10<sup>th</sup> of Ramadan City - Egypt

Tel.: ++(2015) 413015 - 413015 Fax. : ++2015 413009 Internet [www.minapharm.com](http://www.minapharm.com)

شركة مينافارم للأدوية والصناعات الكيماوية  
ط ٢ ش. البرديس - أرض الفلف  
خلف الرقابة الإدارية - أرض الفلف

**Agree**


We acknowledge that the above-mentioned statements are extracted from the Company's financial statements issued by the Board of Directors held on 2 / 12 / 2024 and have not yet issued the auditor's report and we undertake to promptly disclose to FRA and EGX if any change in these statements as soon as it occurs until the submission of the signed financial statements which we undertake to send immediately after Issue the auditor/auditor's report before the beginning of the trading session of the following day according to the date recorded in the auditor's report, which we expect to be a " clean" report .

**Investor relations officer**



Date 2024/12/2

**Chairman**



**The company's stamp.**

شركة مينافارم للأدوية والصناعات الكيماوية  
ط ٢ ش. البرديس من أسماء فهمي  
خلف الرقابة الإدارية - أرض الجولف

**Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt**  
**Factory: 10<sup>th</sup> of Ramadan City - Egypt**

Tel.: ++(2015) 413015 - 413015 Fax. : ++2015 413009 Internet [www.minapharm.com](http://www.minapharm.com)